scholarly journals Analgesic effect and possible mechanism of SCH772984 intrathecal injection on rats with bone cancer pain

2016 ◽  
Vol 24 (3) ◽  
pp. 354-362 ◽  
Author(s):  
Juhua Bian ◽  
Shanshan Zhu ◽  
Wenwen Ma ◽  
Chunwei Li ◽  
Muhammad Aqeel Ashraf
Keyword(s):  
Cancer Pain ◽  
Analgesic Effect ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Bone Cancer Pain

Blocking EphB1 Receptor Forward Signaling in Spinal Cord Relieves Bone Cancer Pain and Rescues Analgesic Effect of Morphine Treatment in Rodents

2011 ◽  
Vol 71 (13) ◽  
pp. 4392-4402 ◽  
Author(s):  
Su Liu ◽  
Wen-Tao Liu ◽  
Yue-Peng Liu ◽  
Hai-Long Dong ◽  
Mark Henkemeyer ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Analgesic Effect ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Morphine Treatment

scholarly journals Rosiglitazone Alleviates Mechanical Allodynia of Rats with Bone Cancer Pain through the Activation of PPAR-γ to Inhibit the NF-κB/NLRP3 Inflammatory Axis in Spinal Cord Neurons

PPAR Research ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-18
Author(s):  
Jie Fu ◽  
Baoxia Zhao ◽  
Chaobo Ni ◽  
Huadong Ni ◽  
Longsheng Xu ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Cancer Pain ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Receptor Protein ◽  
Bone Cancer Pain ◽  
Dependent Manner ◽  
Concurrent Administration ◽  
Spinal Cord Neurons ◽  
Ppar Γ

Bone cancer pain (BCP) is a serious clinical problem that affects the quality of life of cancer patients. However, the current treatment methods for this condition are still unsatisfactory. This study investigated whether intrathecal injection of rosiglitazone modulates the noxious behaviors associated with BCP, and the possible mechanisms related to this effect were explored. We found that rosiglitazone treatment relieved bone cancer-induced mechanical hyperalgesia in a dose-dependent manner, promoted the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) in spinal cord neurons, and inhibited the activation of the nuclear factor-kappa B (NF-κB)/nod-like receptor protein 3 (NLRP3) inflammatory axis induced by BCP. However, concurrent administration of the PPAR-γ antagonist GW9662 reversed these effects. The results show that rosiglitazone inhibits the NF-κB/NLRP3 inflammation axis by activating PPAR-γ in spinal neurons, thereby alleviating BCP. Therefore, the PPAR-γ/NF-κB/NLRP3 signaling pathway may be a potential target for the treatment of BCP in the future.

scholarly journals Intrathecal Substance P-Saporin in the Dog

2013 ◽  
Vol 119 (5) ◽  
pp. 1178-1185 ◽  
Author(s):  
Dorothy Cimino Brown ◽  
Kimberly Agnello
Keyword(s):  
Substance P ◽  
Cancer Pain ◽  
Antinociceptive Effect ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Standard Of Care ◽  
Bone Cancer Pain ◽  
Controlled Study ◽  
Control Group ◽  
Analgesic Therapy

Abstract Background: Substance P-saporin (SP-SAP), a chemical conjugate of substance P and a recombinant version of the ribosome-inactivating protein, saporin, when administered intrathecally, acts as a targeted neurotoxin producing selective destruction of superficial neurokinin-1 receptor–bearing cells in the spinal dorsal horn. The goal of this study was to provide proof-of-concept data that a single intrathecal injection of SP-SAP could safely provide effective pain relief in spontaneous bone cancer pain in companion (pet) dogs. Methods: In a single-blind, controlled study, 70 companion dogs with bone cancer pain were randomized to standard-of-care analgesic therapy alone (control, n = 35) or intrathecal SP-SAP (20–60 µg) in addition to standard-of-care analgesic therapy (n = 35). Activity, pain scores, and videography data were collected at baseline, 2 weeks postrandomization, and then monthly until death. Results: Although the efficacy results at the 2-week postrandomization point were equivocal, the outcomes evaluated beyond 2 weeks revealed a positive effect of SP-SAP on chronic pain management. Significantly, more dogs in the control group (74%) required unblinding and adjustment in analgesic protocol or euthanasia within 6 weeks of randomization than dogs that were treated with SP-SAP (24%; P < 0.001); and overall, dogs in the control group required unblinding significantly sooner than dogs that had been treated with SP-SAP (P < 0.01). Conclusion: Intrathecal administration of SP-SAP in dogs with bone cancer produces a time-dependent antinociceptive effect with no evidence of development of deafferentation pain syndrome which can be seen with neurolytic therapies.

scholarly journals The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain

2016 ◽  
Vol 38 (5) ◽  
pp. 1433-1442 ◽  
Author(s):  
Chi-Hua Guo ◽  
Lu Bai ◽  
Huang-Hui Wu ◽  
Jing Yang ◽  
Guo-Hong Cai ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Analgesic Effect ◽  
Bone Cancer ◽  
Bone Cancer Pain

scholarly journals Inducible Lentivirus-Mediated siRNA against TLR4 Reduces Nociception in a Rat Model of Bone Cancer Pain

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Ruirui Pan ◽  
Huiting Di ◽  
Jinming Zhang ◽  
Zhangxiang Huang ◽  
Yuming Sun ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Pain Treatment ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Bone Cancer Pain ◽  
Prolonged Treatment ◽  
Small Interference Rna ◽  
Long Term Treatment ◽  
Walker 256

Although bone cancer pain is still not fully understood by scientists and clinicians alike, studies suggest that toll like receptor 4 (TLR4) plays an important role in the initiation and/or maintenance of pathological pain state in bone cancer pain. A promising treatment for bone cancer pain is the downregulation of TLR4 by RNA interference; however, naked siRNA (small interference RNA) is not effective in long-term treatments. In order to concoct a viable prolonged treatment for bone cancer pain, an inducible lentivirus LvOn-siTLR4 (tetracycline inducible lentivirus carrying siRNA targeting TLR4) was prepared and the antinociception effects were observed in bone cancer pain rats induced by Walker 256 cells injection in left leg. Results showed that LvOn-siTLR4 intrathecal injection with doxycycline (Dox) oral administration effectively reduced the nociception induced by Walker 256 cells while inhibiting the mRNA and protein expression of TLR4. Proinflammatory cytokines as TNF-αand IL-1βin spinal cord were also decreased. These findings suggest that TLR4 could be a target for bone cancer pain treatment and tetracycline inducible lentivirus LvOn-siTLR4 represents a new potential option for long-term treatment of bone cancer pain.

Sign in / Sign up

Export Citation Format

Share Document